Synlogic Recruiting Adult Patients for Phase 2 Trial of SYNB1618

Synlogic Recruiting Adult Patients for Phase 2 Trial of SYNB1618

284386

Synlogic Recruiting Adult Patients for Phase 2 Trial of SYNB1618

Synlogic is recruiting patients for a proof-of-concept Phase 2 trial that is investigating SYNB1618, its investigational treatment for phenylketonuria (PKU), in adults with the disease. The open-label trial (NCT04534842), initially delayed due to the COVID-19 pandemic, seeks to enroll 12 adult patients who failed to respond, or did not tolerate, other PKU approved therapies, such as Kuvan (sapropterin dihydrochloride) or Palynziq (pegvaliase-pqpz). Recruitment for the SynPheny-1 trial is underway at several clinical sites across the…

You must be logged in to read/download the full post.